With over ten years of data on Cesium-131, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online. A Matched Pair Analysis Of Clinical Outcomes...
Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World’s Premier Radiation Oncology Society RICHLAND, WASHINGTON – November 24, 2020 – The importance of Isoray, Inc.’s (NYSE American: ISR) Cesium-131 in treating prostate and brain...
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – November 2, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
RICHLAND, Wash., October 20, 2020 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 18,269,230 shares of its...
RICHLAND, Wash., October 19, 2020 -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year RICHLAND, WASHINGTON – September 17, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment...
RICHLAND, WASHINGTON – September 16, 2020 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori...
Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a...
WCBS CEO Radio looks at the data that points to Cesium-131 as an effective cancer-fighting treatment option with CEO Lori Woods and an upcoming study that will look at its use in treating head and neck cancers. https://youtu.be/lbGVv5FpJnc
Beneath the COVID-19 headlines, WCBS’ CEO Radio talks with Isoray CEO Lori Woods about Cesium-131 internal radiation therapy and making a difference in treating people with cancer. https://youtu.be/HU0RdDcpEKY
Expect to hear more about promising treatments like Cesium-131 internal radiation therapy says WCBS’s CEO Radio host Ray Hoffman talking with Isoray CEO Lori Woods about treating cancer during COVID-19. https://youtu.be/gy00P0pNetw